A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living with small cell lung cancer (SCLC).

Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant ...

Elena Elimova, MD, shares efficacy data for zanidatamab in patients with HER2-positive gastroesophageal adenocarcinoma from ...

Molecular profiling enabled targeted treatment that significantly improved survival in advanced cholangiocarcinoma. Learn ...

Zanidatamab plus chemotherapy delays progression or death in patients with untreated locally advanced or metastatic gastroesophageal adenocarcinoma.

China NMPA accepts and grants priority review status to Hutchmed’s NDA for fanregratinib in second-line intrahepatic cholangiocarcinoma: Hong Kong, Shanghai Wednesday, December ...

The NDA is supported by data from a single-arm, multi-center, open-label, Phase II registration study in China that completed enrollment of 87 patients in March.

NDA supported by results from a Phase II registration trial in China - - Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in comparison ...

(Alliance News) - Hutchmed China Ltd on Monday said Chinese regulators have accepted a new drug application for its cancer treatment fanregratinib and granted it priority review status.

NDA supported by results from a Phase II registration trial in China —— Second most common form of liver cancer after hepatocellular carcinoma, ...

HUTCHMED (China) ( ($HK:0013) ) has issued an update. HUTCHMED has announced that China’s National Medical Products Administration has accepted ...

Advanced biliary tract cancer represents one of the most challenging gastrointestinal malignancies in China, with increasing ...